Acute aflatoxin B1 – Induced hepatotoxicity alters gene expression and disrupts lipid and lipoprotein metabolism in rats. (2017)

• Record Type: Journal Article
• Authors: Rotimi, Oluwakemi Anuoluwapo; Rotimi, Solomon Oladapo; Duru, Chibueze Uchechukwu; Ebebeinwe, Ogheneworo Joel; Abiodun, Anthonia Obhio; Oyeniyi, Boluwaji Oluwamayowa; Faduyile, Francis Adedayo
• Is Part Of: Toxicology reports. Volume 4(2017)
• Page Start: 408
• Page End: 414
• Publication Date: 2017
• Subjects: Ahr aryl hydrocarbon receptor -- Cpt1a carnitine palmitoyl transferase 1A -- Lipc hepatic lipoprotein lipase -- Lcat lecithin – cholesterol acyltransferase -- Scarb1 scavenger receptor class B member 1; Aflatoxin B1 -- Liver -- Lipid -- Lipoprotein -- Gene expression; Toxicology -- Periodicals; Clinical toxicology -- Periodicals; Drug-Related Side Effects and Adverse Reactions; Hazardous Substances; Poisoning; Toxicology; Electronic journals; Periodicals; Periodicals; 571.9505
• DOI: 10.1016/j.toxrep.2017.07.006
• Languages: English
• ISSNs: 2214-7500

Abstract

Graphical abstract: Highlights: Aflatoxin B1 is a natural food toxicant that induces hepatotoxicity. Acute exposure to aflatoxin B1 increased plasma and liver lipids, and downregulated CPT1 while SCARB was upregulated. The dysregulation of lipid and lipoprotein metabolizing genes may be associated with increasing the risk of CHD. Abstract: In this study, alterations in lipid metabolism associated with acute aflatoxin B1 (AFB1) induced hepatotoxicity and gene expression changes underlying these effects were investigated. Rats were orally administered three doses (0.25 mg/kg, 0.5 mg/kg and 1.0 mg/kg) of AFB1 for seven days; after which blood was collected and liver excised. Lipid profiles of plasma and liver were determined spectrophotometrically while the expression of genes associated with lipid and lipoprotein metabolism was assayed by reverse transcriptase polymerase chain reaction. Acute exposure to AFB1 increased the levels of plasma and liver cholesterol, triglycerides and phospholipids. AFB1 at 0.5 mg/kg and 1.0 mg/kg resulted in a dose-dependent (1.2 and 1.5 fold, respectively) downregulation of hepatic Cpt1a with a concomitant 1.2 and 1.5 fold increase in the level of plasma FFA, respectively. A similar observation of 1.2 and 1.3 fold increase was also observed in plasma triglyceride concentration, at both respective doses. AFB1 also decreased the relative expression of Ahr, Lipc and Lcat whereas, it upregulated Scarb1 in a dose dependent manner. AFB1-induced dysregulation of the expression of lipid and lipoprotein metabolizing genes may be one mechanism linking AFB1 to altered lipid metabolism and ultimately risk for coronary heart disease.